Lobbying Filing Details

Total Spending

$740,000

Activities

4

Lobbyists

3

Gov't Entities

8

Filing Information
Filing UUID:
482b9f27-ecb6-4314-a58e-266116a7677a
Type:
Q4 - 4th Quarter - Report
Period:
2016 - 4th Quarter (Oct 1 - Dec 31)
Date Posted:
January 23, 2017 at 9:17 PM
Income:
$0
Expenses:
$740,000
Expense Method:
Method A - Reporting amounts using LDA definitions only
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Joseph Devaney
Registrant
ASTELLAS PHARMA US, INC.

Pharmaceuticals

Northbrook, Illinois
Client
ASTELLAS PHARMA US, INC.
Illinois, United States of America
Lobbying Activities (4)
Activity 1
Copyright/Patent/Trademark

Issues related to various patent reform bills (H.R.9, S.632, S.1137).

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (3)
  • MRS. MARY LACEY REUTHER
  • MS. MELISSA WIER BANASHAK
  • SARAH CHRISTINE D'ORSIE
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 2
Health Issues

Issues related to the implementation of healthcare reform (P.L.111-148, P.L.111-152); Issues related to oral chemotherapy in The Cancer Drug Coverage Parity Act (S.1566, H.R.2739); The 21st Century Cures Act (H.R.6); Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues; Value of Prescription Drugs, Senate & House; Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (3)
  • MRS. MARY LACEY REUTHER
  • MS. MELISSA WIER BANASHAK
  • SARAH CHRISTINE D'ORSIE
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 3
Medicare/Medicaid

Issues related to the implementation of health care reform (P.L.111-148, P.L.111-152); Issues related to the Medicare hospital outpatient issues (H.R.1178, S.1466); Developing an Innovative Strategy for Antimicrobial Resistance Microorganisms Act of 2015 (DISARM) (H.R.512); Medicare Program; Part B Drug Payment Model, Proposed rule, CMS-1670-P (March 11, 2016) - Provisions related to the Medicare Part B Drug Payment Model; H.R. 5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models - Suspending the Part B Drug Payment Model; Medicare Part D rebates policy issues.

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (3)
  • MRS. MARY LACEY REUTHER
  • MS. MELISSA WIER BANASHAK
  • SARAH CHRISTINE D'ORSIE
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES
Activity 4
Taxation/Internal Revenue Code

Proposed Regulations under IRC Sec. 385 regarding their impact on the ability of U.S. subsidiaries to invest and grow in the United States and the competitiveness of the United States as a location for foreign direct investment.

Foreign Entity Issues: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.

Lobbyists (3)
  • MRS. MARY LACEY REUTHER
  • MS. MELISSA WIER BANASHAK
  • SARAH CHRISTINE D'ORSIE
Government Entities (2)
  • SENATE
  • HOUSE OF REPRESENTATIVES

Source: LDA.gov, data retrieved November 9, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.